Latest News - Vertex Pharmaceuticals
Top Corporates Hub
Vertex Pharmaceuticals
Assessing Vertex Pharmaceuticals (VRTX) Valuation After Recent Share Price Weakness
21.05.2026 11:11
Vertex Pharmaceuticals (VRTX) stock has moved lower recently, with the price down about 2% over the past month and roughly 8% over the past 3 months, prompting closer attention from investors. See our latest analysis for Vertex Pharmaceuticals. Zooming out, Vertex’s recent share price weakness, including a 1-day share price return of down 0.89% and a 7-day share price return of down 4.99%, sits against a 5-year total shareholder return of 108.14%. This points to fading short term momentum...
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data Looms
16.05.2026 00:12
CRISPR Therapeutics (NASDAQ:CRSP) Chief Executive Officer Sam Kulkarni said the company is entering a “second phase” as it moves beyond the initial launch of CASGEVY and prepares for data from multiple pipeline programs over the next 12 to 18 months. Speaking at a Bank of America fireside chat host
Entrada Therapeutics DMD Trial Shows Early Functional Gains, Clean Safety Profile
09.05.2026 06:07
Entrada Therapeutics (NASDAQ:TRDA) said initial data from the first cohort of its phase I/II ELEVATE-44-201 trial showed favorable safety and tolerability and early functional improvement in ambulatory patients with Duchenne muscular dystrophy, or DMD, who have mutations amenable to exon 44 skipping
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
08.05.2026 13:00
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
08.05.2026 13:00
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
06.05.2026 12:45
Vertex Pharmaceuticals Incorporated beat Q1 2026 earnings, but CF growth is slowing and diversification faces hurdles. Click for this VRTX update.
Vertex Pharmaceuticals Q1 Earnings Review: Pharma May Need Bolder M&A Strategy
06.05.2026 12:45
Vertex Pharmaceuticals Incorporated beat Q1 2026 earnings, but CF growth is slowing and diversification faces hurdles. Click for this VRTX update.
Barclays Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $615
06.05.2026 11:43
Barclays analyst Eliana Merle maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Overweight and raises the price target from $607 to $615.
BRUCE SACHS Backs Up Beliefs With A Notable Acquisition Of Vertex Pharmaceuticals Stock Options Worth $9K
06.05.2026 11:03
BRUCE SACHS Backs Up Beliefs With A Notable Acquisition Of Vertex Pharmaceuticals Stock Options Worth $9K
06.05.2026 11:03
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
06.05.2026 11:01
BOSTON, May 06, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia.
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
06.05.2026 11:01
BOSTON, May 06, 2026--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). This agreement secures sustainable access to this innovative one-time treatment for eligible patients in Germany ages 12 years and older living with severe sickle cell disease or transfusion-dependent beta thalassemia.
Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price Weakness
06.05.2026 10:08
Wondering if Vertex Pharmaceuticals at around US$424 per share is still a solid opportunity or if the easy gains are behind it? This article focuses squarely on what the current price might represent for you. The stock has had a mixed run, with a 1.3% decline over the last week, a 3.3% decline over the last month, a 6.1% decline year to date and a 5.7% decline over the past year, set against longer term returns of 23.1% over three years and 99.2% over five years. Recent coverage of Vertex...
Is It Too Late To Consider Vertex Pharmaceuticals (VRTX) After Recent Share Price Weakness
06.05.2026 10:08
Wondering if Vertex Pharmaceuticals at around US$424 per share is still a solid opportunity or if the easy gains are behind it? This article focuses squarely on what the current price might represent for you. The stock has had a mixed run, with a 1.3% decline over the last week, a 3.3% decline over the last month, a 6.1% decline year to date and a 5.7% decline over the past year, set against longer term returns of 23.1% over three years and 99.2% over five years. Recent coverage of Vertex...
NKF Honors Vertex with 2026 Kidney Biotech Innovation Award
06.05.2026 10:00
Vertex has been selected to receive the 2026 Kidney Biotech Innovation Award from the National Kidney Foundation (NKF) at the 2026 Spring Clinical Meetings in New Orleans.
Is This Millionaire-Maker Biotech Stock a Buy Right Now?
06.05.2026 07:50
The market wasn't impressed by its latest quarterly update.
Is This Millionaire-Maker Biotech Stock a Buy Right Now?
06.05.2026 07:50
The market wasn't impressed by its latest quarterly update.
Vertex Pharmaceuticals Incorporated 2026 Q1 - Results - Earnings Call Presentation
06.05.2026 02:07
2026-05-06. The following slide deck was published by Vertex Pharmaceuticals Incorporated in conjunction with their 2026 Q1 earnings call.